InvestorsHub Logo
Followers 19
Posts 2085
Boards Moderated 7
Alias Born 04/27/2009

Re: None

Thursday, 10/19/2023 8:26:15 PM

Thursday, October 19, 2023 8:26:15 PM

Post# of 448
On July 30, 2023, the Company entered into an Asset Purchase Agreement with Sumitomo Pharma Co., Ltd., or Sumitomo, pursuant to which Sumitomo agreed to (i) purchase, among other things, the Company’s assets and rights related to the development, manufacture, marketing and commercialization of XENLETA in the People’s Republic of China, Hong Kong, Macau and Taiwan, or collectively the Territory, and (ii) assume certain liabilities related to the acquired assets. The transactions contemplated by the Asset Purchase Agreement closed on July 30, 2023. At the closing, Sumitomo made an upfront cash payment of $15.0 million, of which (i) $1.8 million was held back as security for potential indemnification claims, (ii) $10.4 million was paid by Sumitomo, on behalf of the Company, to certain of the Company’s contract manufacturing organizations to settle and discharge the remaining obligations under such agreements and (iii) $2.8 million was paid to the Company in cash. The cash received by the Company is not reflected on the balance sheet at June 30, 2023.